Literature DB >> 20823710

Remodelling of the heart and vessels in experimental hypertension: advances in protection.

Fedor Simko1, Olga Pechanova.   

Abstract

Left ventricular hypertrophy (LVH), despite its adaptive nature, increases cardiovascular morbidity and mortality. Novel approaches for protection against pathological heart remodelling are presented in this supplement. Melatonin diminishes myocardial fibrosis in rats exposed to continuous light and N-nitro-L-arginine-methyl ester (L-NAME) treatment and reduces production of endothelium-derived constricting factors in L-NAME-induced hypertension. Melatonin, because of its extraordinary antioxidant and scavenging properties, benefits for endothelium and sympatholytic action, may prove to be a useful protective drug against heart remodelling. In hypertension induced by relative aldosteronism, the correction of macro and micronutrient dyshomeostasis appears to act beneficially within pathological myocardial remodelling. Alterations in the signal cascade of pathological myocardial growth, including humoral stimuli, receptors, intracellular messengers or transcriptional factors, may be favourably modified at different levels. Inhibition of nuclear factor kappa B (NF-kappaB) potentiates hypertension development, enhances oxidative load, increases the cross-sectional area of the aorta and reduces nitric oxide (NO) synthase activity in L-NAME hypertension. It is suggested that NF-kappaB may play a protective rather than a deleterious role in the haemodynamically overloaded circulation. Compound 21, a recently developed peptide angiotensin II type 2 (AT2) receptor agonist, offers a novel approach in investigating the role of AT2 receptors in the protection of the hypertensive heart. A novel NO donor, L-419, with its intrinsic protection of NO, improves the entire NO signalling cascade and thus favourably influencing the response of the left ventricle to haemodynamic overload. LVH prevention or regression should be considered a therapeutic success only when, along with hypertrophied mass reduction, an improvement of the heart structure, function, metabolism and electrical stability is achieved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823710     DOI: 10.1097/01.hjh.0000388487.43460.db

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

1.  Impaired cardiac ischemic tolerance in spontaneously hypertensive rats is attenuated by adaptation to chronic and acute stress.

Authors:  T Ravingerová; I Bernátová; J Matejíková; V Ledvényiová; M Nemčeková; O Pecháňová; N Tribulová; J Slezák
Journal:  Exp Clin Cardiol       Date:  2011

Review 2.  Cardiac NO signalling in the metabolic syndrome.

Authors:  O Pechánová; Z V Varga; M Cebová; Z Giricz; P Pacher; P Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney.

Authors:  Lakshmi Pulakat; Vincent G DeMarco; Adam Whaley-Connell; James R Sowers
Journal:  Cardiorenal Med       Date:  2011-04-15       Impact factor: 2.041

Review 4.  Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension.

Authors:  Natalia Jorgelina Prado; León Ferder; Walter Manucha; Emiliano Raúl Diez
Journal:  Curr Hypertens Rep       Date:  2018-05-09       Impact factor: 5.369

5.  Long-term electronic cigarette exposure induces cardiovascular dysfunction similar to tobacco cigarettes: role of nicotine and exposure duration.

Authors:  Mohamed A El-Mahdy; Elsayed M Mahgoup; Mohamed G Ewees; Mahmoud S Eid; Tamer M Abdelghany; Jay L Zweier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-02-19       Impact factor: 4.733

6.  Hypertension and cardiovascular remodelling in rats exposed to continuous light: protection by ACE-inhibition and melatonin.

Authors:  Fedor Simko; Olga Pechanova; Kristina Repova Bednarova; Kristina Krajcirovicova; Peter Celec; Natalia Kamodyova; Stefan Zorad; Jarmila Kucharska; Anna Gvozdjakova; Michaela Adamcova; Ludovit Paulis
Journal:  Mediators Inflamm       Date:  2014-07-06       Impact factor: 4.711

7.  Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril.

Authors:  Fedor Simko; Olga Pechanova; Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Peter Celec; Lubomira Tothova; Stanislava Vrankova; Lucia Balazova; Stefan Zorad; Michaela Adamcova
Journal:  Int J Mol Sci       Date:  2017-07-25       Impact factor: 5.923

Review 8.  Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities.

Authors:  M P M Graham-Brown; A S Patel; D J Stensel; D S March; A-M Marsh; J McAdam; G P McCann; J O Burton
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

9.  Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients.

Authors:  Matthew P M Graham-Brown; Elaine Rutherford; E Levelt; Daniel S March; Darren R Churchward; David J Stensel; Christie McComb; Kenneth Mangion; Samantha Cockburn; Colin Berry; James C Moon; Patrick B Mark; James O Burton; Gerry P McCann
Journal:  J Cardiovasc Magn Reson       Date:  2017-02-27       Impact factor: 5.364

10.  Short-Term Treatment with Esmolol Reverses Left Ventricular Hypertrophy in Adult Spontaneously Hypertensive Rats via Inhibition of Akt/NF-κB and NFATc4.

Authors:  Begoña Quintana-Villamandos; David A Goukassian; Sharath P Sasi; Emilio Delgado-Baeza
Journal:  Biomed Res Int       Date:  2018-02-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.